TRPML1: A Lysosomal Guardian of Mitochondrial Health in Heart Failure
A new study identifies a crucial interorganelle signaling axis, revealing that the lysosomal protein TRPML1 protects mitochondria and could serve as a therapeutic target to prevent the progression of cardiac hypertrophy to heart failure.
Key Findings
A study published in the journal Engineering reports that transient receptor potential mucolipin 1 (TRPML1) preserves mitochondrial function and directly alleviates cardiac hypertrophy. This is achieved by inhibiting the oligomerization of voltage-dependent anion channel 1 (VDAC1) on the outer mitochondrial membrane. Furthermore, transcriptomic analyses of heart failure samples from both mice and humans show a consistent downregulation of TRPML1 expression.
Experimental Evidence
- In animal models, cardiomyocyte-specific overexpression or pharmacological activation of TRPML1 preserved cardiac function, lowered mitochondrial oxidative stress, and boosted energy production.
- Conversely, cardiomyocyte-specific deletion or pharmacological inhibition of TRPML1 worsened cardiac hypertrophy and mitochondrial dysfunction.
Mechanism of Action
The mechanism operates through a direct physical interaction. The C-terminal domain of TRPML1 binds directly to the N-terminal domain of VDAC1, effectively suppressing VDAC1 oligomerization. This action preserves mitochondrial calcium homeostasis and maintains the critical balance between mitochondrial fusion and fission. Supporting this pathway, treatment with NSC 15364, a small-molecule inhibitor of VDAC1 oligomerization, partially reversed cardiac hypertrophy in TRPML1-deficient mice.
Regulation and Downstream Signaling
The study also identified the transcriptional regulation of TRPML1. Signal transducer and activator of transcription 5B (Stat5b) was identified as a transcriptional regulator of TRPML1 during cardiac hypertrophy. Under physiological conditions, Stat5b binds to the TRPML1 promoter and enhances its expression; however, this regulatory axis is impaired under hypertrophic stress.
Conclusion
The findings establish a critical interorganelle communication axis between lysosomes and mitochondria, with lysosomal TRPML1 acting as a guardian of mitochondrial integrity. This positions TRPML1 as a promising therapeutic candidate to slow the transition from pathological cardiac hypertrophy to heart failure.